Pleural Mesotheliomas Recruiting Phase 2 Trials for Durvalumab (DB11714)

Also known as: Pleural Mesothelioma

IndicationStatusPhase
DBCOND0029910 (Pleural Mesotheliomas)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02588131A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)Treatment